Medera Completes Patient Dosing for Heart Failure Treatment

Exec Edge

12 Mar

By Karen Roman

Biopharmaceutical company Medera Inc. said it finished patient dosing in the trial of SRD-001, its gene therapy candidate for heart failure with reduced ejection fraction.

Additionally, Medera and Keen Vision Acquisition Corporation (Nasdaq: KVAC) announced they had entered into a definitive merger agreement on September 2024.

“We are very excited and encouraged by these results, which indicate that our various new designs such as optimized dosages seem to be making differences,” said Ronald Li, Ph.D., Medera’s co-founder and CEO.

Contact:

Healthcare Edge

Editor@Executives-edge.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2518722078"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2518722078\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2518722078?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-12 00:53","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2518722078","market":"us","top_or_hot":-1,"title":"Medera Completes Patient Dosing for Heart Failure Treatment","media":"Exec Edge","content":"<html><body><p><img height=\"613\" src=\"https://s.yimg.com/uu/api/res/1.2/kMMivdIcXpjaMdge7IF85Q--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/exec_edge_220/7c2dfdf3d3e07831beb7060ea5cdae12\" width=\"2117\"/></p>\n<p>By Karen Roman</p>\n<p>Biopharmaceutical company Medera Inc. said it finished patient dosing in the trial of SRD-001, its gene therapy candidate for heart failure with reduced ejection fraction.</p>\n<p>Additionally, Medera and Keen Vision Acquisition Corporation (Nasdaq: KVAC) announced they had entered into a definitive merger agreement on September 2024.</p>\n<p>“We are very excited and encouraged by these results, which indicate that our various new designs such as optimized dosages seem to be making differences,” said Ronald Li, Ph.D., Medera’s co-founder and CEO.</p>\n<div>\n<div>\n  Contact:\n </div>\n</div>\n<p><strong>Healthcare Edge</strong></p>\n<p>Editor@Executives-edge.com</p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medera Completes Patient Dosing for Heart Failure Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedera Completes Patient Dosing for Heart Failure Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-12 00:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/medera-completes-patient-dosing-heart-165330309.html><strong>Exec Edge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Karen Roman\nBiopharmaceutical company Medera Inc. said it finished patient dosing in the trial of SRD-001, its gene therapy candidate for heart failure with reduced ejection fraction.\nAdditionally,...</p>\n\n<a href=\"https://finance.yahoo.com/news/medera-completes-patient-dosing-heart-165330309.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KVAC","symbol_name":"KEEN VISION ACQUISITION CORPORATION","start_time":0,"source_url":"https://finance.yahoo.com/news/medera-completes-patient-dosing-heart-165330309.html","article_id":"2518722078","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518722078","pubTimestamp":1741712010,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Biopharmaceutical company Medera Inc. said it finished patient dosing in the trial of SRD-001, its gene therapy candidate for heart failure with reduced ejection fraction.Additionally, Medera and Keen Vision Acquisition Corporation  announced they had entered into a definitive merger agreement on September 2024.“We are very excited and encouraged by these results, which indicate that our various new designs such as optimized dosages seem to be making differences,” said Ronald Li, Ph.D., Medera’s co-founder and CEO.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"KVAC":"KEEN VISION ACQUISITION CORPORATION","KVACU":"Keen Vision Acquisition Corp.","KVACW":"KEEN VISION ACQUISITION CORPORATION C/WTS 15/03/2028 (TO PUR ORD)"},"translate_title":"Medera完成心力衰竭治疗患者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KVAC":0.9,"KVACU":0.9,"KVACW":0.6},"content_text":"By Karen Roman\nBiopharmaceutical company Medera Inc. said it finished patient dosing in the trial of SRD-001, its gene therapy candidate for heart failure with reduced ejection fraction.\nAdditionally, Medera and Keen Vision Acquisition Corporation (Nasdaq: KVAC) announced they had entered into a definitive merger agreement on September 2024.\n“We are very excited and encouraged by these results, which indicate that our various new designs such as optimized dosages seem to be making differences,” said Ronald Li, Ph.D., Medera’s co-founder and CEO.\n\n\n  Contact:\n \n\nHealthcare Edge\nEditor@Executives-edge.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}